Impact of baseline proteinuria level on long-term outcomes in lupus nephritis
Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes. We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, g...
Saved in:
Published in | Rheumatology (Oxford, England) |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
24.10.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes.
We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes.
At baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3.The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis.
Low-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes. |
---|---|
AbstractList | Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes.OBJECTIVESProteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes.We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes.METHODSWe included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes.At baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3.The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis.RESULTSAt baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3.The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis.Low-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes.CONCLUSIONSLow-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes. Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes. We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes. At baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3.The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis. Low-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes. Abstract Objectives Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes. Methods We included 249 patients diagnosed with their first biopsy-proven LN. We divided patients based on baseline proteinuria into low-level (≤1 g/day, group 1; 62 patients), moderate-level (>1 and <3 g/day, group 2; 90 patients), and high-level proteinuria (≥3 g/day, group 3; 97 patients). Outcomes included complete proteinuria recovery (CPR) at 1 year, an adverse composite outcome (ESKD, a sustained ≥40% decline in eGFR, or death), and LN flares. Cox proportional hazard models were used to examine the association between baseline characteristics and long-term outcomes. Results At baseline, the median [IQR] age was 33.2 [26.4, 42.4] years; median proteinuria level was 2.2 [1.0, 3.8] g/day. 177 (71%) patients had proliferative lesions on biopsy; 59.7% in group 1, 78.9% in group 2, and 71.4% in group 3. The rate of achievement of CPR at 1 year was highest for group 1 and lowest for group 3. For long-term outcomes (median follow-up 8.4 years), the frequency of the adverse composite outcome was 27.4%, 26.7%, and 48.5% in groups 1, 2, and 3, respectively; p= 0.003. The corresponding frequency of flares was 27.4%, 38.2%, and 61.9%, respectively; p< 0.001. In the multivariable model for factors associated with long-term outcomes, there was no significant difference between groups 1 and 2; group 3 was associated with the worst prognosis. Conclusions Low-level proteinuria is commonly associated with proliferative LN and adverse long-term outcomes. |
Author | Li, Qixuan Kharouf, Fadi Touma, Zahi Whittall Garcia, Laura P Gladman, Dafna D |
Author_xml | – sequence: 1 givenname: Fadi surname: Kharouf fullname: Kharouf, Fadi organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa – sequence: 2 givenname: Qixuan surname: Li fullname: Li, Qixuan organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa – sequence: 3 givenname: Laura P surname: Whittall Garcia fullname: Whittall Garcia, Laura P organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa – sequence: 4 givenname: Dafna D surname: Gladman fullname: Gladman, Dafna D organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa – sequence: 5 givenname: Zahi orcidid: 0000-0001-5177-2076 surname: Touma fullname: Touma, Zahi organization: University of Toronto Lupus Clinic, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canaa |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39447055$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkMtOwzAQRS1URB_wBwh5ySbUjh9JlqjiUamIDawjO5m0AccOdozUvyeopWI1o9G9M3fOHE2ss4DQNSV3lBRs6XcQOzU447b75ScoEFlxhmaUyzQhjKWTU5_yKZqH8EEIEZTlF2jKCs4zIsQMvay7XlUDdg3WKoBpLeDeuwFaG32rsIFvMNhZbJzdJgP4Drs4VK6DgNtxGvsYsIV-59uhDZfovFEmwNWxLtD748Pb6jnZvD6tV_ebpKI8KxLOda7rXFcSeJ1yQdMcFFWSFyonAFmWc1JLzkUKUhdKNJUaP6KEasm11IIt0O1h7xj1K0IYyq4NFRijLLgYSkZTIgouWTZK-UFaeReCh6bsfdspvy8pKX9Blv9BlkeQo-3meCHqDuqT6Y8c-wEDqXZC |
ContentType | Journal Article |
Copyright | The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
Copyright_xml | – notice: The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1093/rheumatology/keae579 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1462-0332 |
ExternalDocumentID | 10_1093_rheumatology_keae579 39447055 |
Genre | Journal Article |
GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 29P 2WC 354 4.4 48X 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABEJV ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DILTD DU5 D~K E3Z EBS EE~ ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 KAQDR KOP KQ8 KSI KSN L7B M-Z MHKGH N9A NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 RHF RIG ROL ROX RUSNO RW1 RXO TCURE TEORI TJX TR2 VVN WOQ X7H YAYTL YKOAZ YXANX ZKX ZY1 ~91 AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c1479-44b8bd8bc6e4d245128ea1a649a80ee77840d64452e6b9a5fca033101b64b6b53 |
ISSN | 1462-0324 1462-0332 |
IngestDate | Fri Oct 25 20:46:00 EDT 2024 Wed Oct 30 12:26:44 EDT 2024 Tue Oct 29 09:19:46 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | biopsy lupus nephritis systemic lupus erythematosus outcomes proteinuria |
Language | English |
License | The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1479-44b8bd8bc6e4d245128ea1a649a80ee77840d64452e6b9a5fca033101b64b6b53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-5177-2076 |
OpenAccessLink | https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keae579/60072233/keae579.pdf |
PMID | 39447055 |
PQID | 3120594637 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3120594637 crossref_primary_10_1093_rheumatology_keae579 pubmed_primary_39447055 |
PublicationCentury | 2000 |
PublicationDate | 2024-Oct-24 2024-10-24 20241024 |
PublicationDateYYYYMMDD | 2024-10-24 |
PublicationDate_xml | – month: 10 year: 2024 text: 2024-Oct-24 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Rheumatology (Oxford, England) |
PublicationTitleAlternate | Rheumatology (Oxford) |
PublicationYear | 2024 |
SSID | ssj0005138 |
Score | 2.497716 |
Snippet | Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term outcomes.
We... Abstract Objectives Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on... Proteinuria is a marker of lupus nephritis (LN) activity and damage. We aimed to explore the impact of baseline proteinuria level on long-term... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
Title | Impact of baseline proteinuria level on long-term outcomes in lupus nephritis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39447055 https://www.proquest.com/docview/3120594637 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxJsuDxmJWxU2iZ3XEQHbBVQk0K7UWzSOHbaiSlbdRFrx65mxnTTLSyyXqPVhknq-Tsb2N98w9hIDYygKg4ucXIeBFDoLCiWLAJJIaBBhVdgq_uWn9OhEflglqx1X1VaXdOpV9f23dSX_41UcQ79SlewVPDsaxQH8jP7FK3oYr__k4_djiSO9jGzCaHUX1k2Pd59viBBEpwGbtvkaUAyet32HD2JJWPNNf0bqrAbdScJG0zT1y6npMZV1-kwkSHoxcOB904_JBsLHU9i2vdV2PAS9Hhk-libweX3R7_BH3fg6OgtfUAcjGOqyYVdkttiA9nuyb6FuwBOS_bZELCmeu2poH0llGgeh8ENmOuY2NH-J3U7Xajv5gfj1mwGTuHYzl8Wyf3qJjdRCd6guyqmd0lu5zm7EGI-I-bdYTZhAkW14Pj7xUGFZiIOplQNv5XIG84dliU1Pju-w235dwV87kNxl10xzj91ceubEfbZ0WOFtzQes8AlWuMUKbxs-YoUPWOFrHCWs8BErD9jJ4bvjN0eBb6URVJHMikBKlSudqyo1UscSs7zcQASpLCAPjckyXOdrTI2T2KSqgKSuAP2E4VqlUqUqEQ_ZXtM25jHjWtdZJSCpogpkpouc_us6q3QGJjW6nrFgmJ7yzCmmlH9zyoy9GOawxNBG51XQmLY_L0UUk5pQKrIZe-Qmd7RI9dwkBLV_xbs9Ybd2aH3K9rptb55hWtmp5xYUPwBpeX-4 |
link.rule.ids | 315,783,787,27938,27939 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+baseline+proteinuria+level+on+long-term+outcomes+in+lupus+nephritis&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Kharouf%2C+Fadi&rft.au=Li%2C+Qixuan&rft.au=Whittall+Garcia%2C+Laura+P&rft.au=Gladman%2C+Dafna+D&rft.date=2024-10-24&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093%2Frheumatology%2Fkeae579&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_keae579 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |